The FDA approved Recorlev on December 30, 2021, for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome when surgery is not an option or has not been curative.

NexThera Co., Ltd. revealed that it has filed a Phase 1/2a Investigational New Drug application with the U.S. Food and Drug Administration for NT-101.

The FDA first approved Gilenya (fingolimod) on September 21, 2010, for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Zai Lab and argenx Announce China's Approval of Efgartigimod Alfa Subcutaneous Injection for Generalized Myasthenia Gravis.

The FDA granted approval for Tezspire on December 17, 2021, as an add-on maintenance treatment for severe asthma.

Eluminex Biosciences Announces Initial Patient Treatment in Phase 1b LOTUS Study of New Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema (DME).

The combination of these two drugs was approved by the FDA to treat signs and symptoms of BPH, providing relief for men with an enlarged prostate.

Rznomics Inc. Gains Approval in Australia for Clinical Trial of RNA Editing Therapy Targeting RHO Gene in Retinitis Pigmentosa.

Pafolacianine received FDA approval on November 29, 2021. This approval has provided surgeons with a novel tool to enhance the visualization of ovarian cancer lesions, thereby improving surgical outcomes.

Cytonics Reveals Start Of Initial Human Phase 1 Trial For CYT-108 In Individuals With Knee Osteoarthritis.

Maribavir received FDA approval on November 23, 2021. This approval provides a new treatment option for post-transplant patients dealing with refractory CMV infections.

Jul 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.